[Pubmed] Case report: Persistent hypogammaglobulinemia in thymoma-associated myasthenia gravis: the impact of rituximab

[RSS-Bot]

Front Neurol. 2023 May 5;14:1152992. doi: 10.3389/fneur.2023.1152992. eCollection 2023.

ABSTRACT

INTRODUCTION: Rituximab (RTX) showed good efficacy and safety for patients with myasthenia gravis. However, the percentage of peripheral CD20+ B cell may be absent for years after low dose of RTX treatment. Persistent hypogammaglobulinemia and opportunistic infection may occur in patients under treatment of RTX with thymoma relapse.

CASE REPRESENTATION: We report a case of refractory myasthenia gravis. After two doses of 100 mg rituximab, the patient developed transient neutropenia. The peripheral blood CD20+ B cell percentage was 0 more than 3 years. Eighteen months later, the patient's symptoms relapsed with thymoma recurred. She had persistent hypogammaglobulinemia and multiple opportunistic infections.

CONCLUSION: In MG patient under B cell depletion therapy had thymoma relapse, Good's syndrome may induce prolonged B cell depletion, hypogammaglobulinemia and opportunistic infections.

PMID:37213908 | PMC:PMC10196171 | DOI:10.3389/fneur.2023.1152992


Source: https://pubmed.ncbi.nlm.nih.gov/3721390 ... t6+86293ac